UK-based producer of diagnostic reagents LGC has purchased The Native Antigen Company (NAC), a UK-based supplier of recombinant viral and bacterial antigens, antibodies and immunoassays. NAC was among the first companies to offer antigens for SARS-COV-2 on a global scale. The deal adds >60 viral and infectious disease products to LGC’s existing portfolio of assurance tools, immunoassays and probes and primers for molecular diagnostics. Terms not announced.
Keywords: Healthcare Investment Banking, Healthcare M&A, Healthcare mergers, Bio-pharmaceutical, COVID-19